OCU 310

Drug Profile

OCU 310

Alternative Names: Brimonidine/steroid combination therapy; OCU310

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ocugen
  • Class Antiglaucomas; Antihypertensives; Imidazoles; Quinoxalines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 25 Sep 2017 Phase-II clinical trials in Dry eyes (Topical)
  • 25 Sep 2017 Ocugen files an IND application with the US FDA for a proof of concept phase II trial for the treatment of Dry eyes before September 2017
  • 25 Sep 2017 US FDA approves IND application for a proof of concept phase II trial of OCU 310 in Dry eyes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top